CHWALISZ Kristof
No ORCID on file
· 132 papers in corpus
· active 1996-2009
Frequent coauthors
- ELGER Walter 72
- SCHUBERT GERD 72
- STOECKEMANN KLAUS 36
- HAENDLER Bernard 24
- HESS-STUMP Holger 24
- LESSEY Bruce 24
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2009
The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2008
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
2007
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …